Home › Research › Tau biomarkers
Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness
Mikio Shoji. Frontiers in bioscience : a journal and virtual library, 2002-04-01
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Amyloid beta protein 40 (Abeta40) and 42 Abeta42, major components of senile plaque amyloids, are physiological peptides present in the brain, cerebrospinal fluid (CSF) and plasma. The levels of CSF Abeta40 and Abeta42(43) show a U-shaped natural course in normal aging. The increase of Abeta42(43) over 60 years of age is inhibited in Alzheimer's disease (AD). This specific alteration of CSF Abeta42(43) correlates with Abeta deposits in the AD brain providing a biological basis for a biomarker of AD. In the GTT2 study, assays of the CSF Abeta ratio ((Abeta40/ Abeta42(43)) showed a diagnostic sensitivity (59%) and specificity (88%) compared with non-AD type dementia and controls. The levels of the Abeta ratio increased from early to late stages of AD. Combination assays of CSF tau and Abeta ratio provided further efficient diagnostic sensitivity (81%) and specificity (87%). The reliability of the assay may prompt worldwide usage of these CSF biomarkers for Alzheimer's patients.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shoji, M. (2002). Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness. Frontiers in bioscience : a journal and virtual library. https://doi.org/10.2741/a826
Vancouver
Shoji M. Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness. Frontiers in bioscience : a journal and virtual library. 2002. doi:10.2741/a826. PMID: 11897565.
BibTeX
@article{shoji2002-11897565,
author = {Shoji, Mikio},
title = {{Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness}},
journal = {Frontiers in bioscience : a journal and virtual library},
year = {2002},
doi = {10.2741/a826},
pmid = {11897565},
url = {https://doi.org/10.2741/a826}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In the GTT2 study, assays of the CSF Abeta ratio ((Abeta40/ Abeta42(43)) showed a diagnostic sensitivity (59%) and specificity (88%) compared with non-AD type dementia and controls.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 21 of the 56 points we could judge it on, which is 38 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in bioscience : a journal and virtual library) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2002 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 11897565) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 21 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 21 of the 56 points we could judge it on is 38 out of 100. |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.